Najat Khan, Ph.D., is the Chief Data Science Officer and the Global Head of Strategy & Operations for Janssen Research & Development. As Chief Data Science Officer for Janssen R&D, Dr. Khan has end-to-end responsibility to advance the impact of using Data Science in transforming the discovery and development of medicines across Janssen. Dr. Khan’s team is focused on applying Artificial Intelligence, Machine Learning, Digital Health, and regulatory-grade Real-World Evidence to high-impact problems across Janssen’s 6 Therapeutic Areas and Global Functions. In her role as Global Head of R&D Strategy & Operations, Dr. Khan shapes Janssen’s R&D strategy, spanning key pipeline and portfolio decisions to new strategic initiatives to deliver transformational medicines for patients. Dr. Khan received her Ph.D. in Organic Chemistry from the University of Pennsylvania with publications in high-impact journals such as Nature, Proceedings of the National Academy of Sciences. Najat received her B.A. in Chemistry with a minor in Economics from Colgate University. 

About the Lecture

In this talk, Dr. Khan will discuss the application of Data Science and Digital Health to the Janssen portfolio, including how Data Science has been critical to the development of Janssen’s COVID-19 vaccine. Data Science and Digital Health in pharmaceutical research & development (R&D) are evolving rapidly, accelerated by the pandemic.  For Janssen R&D, Data Science, and Digital Health are integrated across their pipeline and are critical for their mission of reimagining how they build transformational medicines for patients. Data Science is already driving impact by improving the probability of success for more definitive therapies/treatments through enhanced evidence generation, as well as conducting more efficient clinical trials, thus accelerating timelines to get medicines to patients faster.